Incidence and risk factors for Graves’ orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves’ disease: investigation of 1,553 cases with newly diagnosed Graves’ disease and proposal of a predictive score-Reference-Cited by-同舟云学术

Incidence and risk factors for Graves’ orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves’ disease: investigation of 1,553 cases with newly diagnosed Graves’ disease and proposal of a predictive score

Published:2023 Issue:11 Volume:70 Page:1087-1096
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Watanabe Natsuko¹^ORCID,Yoshimura Noh Jaeduk¹,Kozaki Ai²,Yoshimura Ran¹,Yoshihara Ai¹,Suzuki Nami¹,Matsumoto Masako¹,Fukushita Miho¹,Kinoshita Aya¹,Aida Azusa¹,Imai Hideyuki¹,Hiruma Shigenori¹,Inoue Toshu²,Inoue Kosuke³,Sugino Kiminori⁴,Ito Koichi⁴

Affiliation:

1. Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan

2. Olympia Eye Hospital, Tokyo 150-0001, Japan

3. Department of Social Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

4. Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0079/_pdf

Reference40 articles.

1. 1 Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf) 63: 395–402.

2. 2 Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, et al. (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376: 1748–1761.

3. 3 Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, et al. (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382: 341–352.

4. 4 Rundle FF, Wilson CW (1945) Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 5: 177–194.

5. 5 Rundle FF (1957) Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism 6: 36–48.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reexamining the Utility of Measuring Thyroperoxidase and Thyroglobulin Antibodies in Medically Treated Graves’ Disease and Orbitopathy;Clinical Thyroidology®;2024-03-01

2. Exacerbation of Thyroid Eye Disease and Dysthyroid Optic Neuropathy During Pregnancy: A Case Report;Internal Medicine;2024

3. Significance of thyroperoxidase and thyroglobulin antibodies in medically treated Graves’ disease;European Thyroid Journal;2023-11-06